Full Report

Format

Full Report
Summary (Text)
Summary (XML)

Send to:

Choose Destination

File
Clipboard
Collections

Refractory Aggressive T-Cell Non-Hodgkin Lymphoma

MedGen UID:: 1791570
•Concept ID:: C5555129
•: Neoplastic Process

Definition

An aggressive T-cell non-Hodgkin lymphoma that is resistant to treatment. [from NCI]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVRefractory Aggressive T-Cell Non-Hodgkin Lymphoma

Hematologic neoplasm
- Lymphoma
  - Non-Hodgkin lymphoma
    - Non-Hodgkin Lymphoma by Clinical Course
      - Aggressive Non-Hodgkin Lymphoma
        Aggressive T-Cell Non-Hodgkin Lymphoma
        Refractory Aggressive T-Cell Non-Hodgkin Lymphoma
        Refractory Adult T-Cell Leukemia/Lymphoma
        Refractory Breast Implant-Associated Anaplastic Large Cell Lymphoma
        Refractory Enteropathy-Associated T-Cell Lymphoma
        Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
        Refractory Hepatosplenic T-Cell Lymphoma
        Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
        Refractory Nasal Type Extranodal NK/T-Cell Lymphoma
        Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
        Refractory T Lymphoblastic Lymphoma

Professional guidelines

PubMed

Critical care management of chimeric antigen receptor T-cell therapy recipients.

Shimabukuro-Vornhagen A, Böll B, Schellongowski P, Valade S, Metaxa V, Azoulay E, von Bergwelt-Baildon M
CA Cancer J Clin 2022 Jan;72(1):78-93. Epub 2021 Oct 6 doi: 10.3322/caac.21702. PMID: 34613616

Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics.

Ahmed Z, Afridi SS, Shahid Z, Zamani Z, Rehman S, Aiman W, Khan M, Mir MA, Awan FT, Anwer F, Iftikhar R
Clin Lymphoma Myeloma Leuk 2021 Nov;21(11):e865-e875. Epub 2021 Jun 24 doi: 10.1016/j.clml.2021.06.012. PMID: 34330673

Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.

Di M, Huntington SF, Olszewski AJ
Oncologist 2021 Feb;26(2):120-132. Epub 2020 Dec 9 doi: 10.1002/onco.13610. PMID: 33230948 Free PMC Article

See all (99)

Recent clinical studies

Etiology

Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.

Trabolsi A, Arumov A, Schatz JH
Blood Cancer J 2024 Feb 8;14(1):27. doi: 10.1038/s41408-024-00997-w. PMID: 38331870 Free PMC Article

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL
Blood 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893. PMID: 36821768 Free PMC Article

CAR T-cell therapy for B-cell lymphoma.

Denlinger N, Bond D, Jaglowski S
Curr Probl Cancer 2022 Feb;46(1):100826. Epub 2021 Dec 25 doi: 10.1016/j.currproblcancer.2021.100826. PMID: 35012754 Free PMC Article

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT
Lancet Oncol 2021 Oct;22(10):1403-1415. Epub 2021 Sep 10 doi: 10.1016/S1470-2045(21)00375-2. PMID: 34516954

Enteropathy-Associated T cell Lymphoma.

Al Somali Z, Hamadani M, Kharfan-Dabaja M, Sureda A, El Fakih R, Aljurf M
Curr Hematol Malig Rep 2021 Apr;16(2):140-147. Epub 2021 May 19 doi: 10.1007/s11899-021-00634-4. PMID: 34009525

See all (256)

Diagnosis

Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.

Trabolsi A, Arumov A, Schatz JH
Blood Cancer J 2024 Feb 8;14(1):27. doi: 10.1038/s41408-024-00997-w. PMID: 38331870 Free PMC Article

How we treat NK/T-cell lymphomas.

Tse E, Zhao WL, Xiong J, Kwong YL
J Hematol Oncol 2022 Jun 3;15(1):74. doi: 10.1186/s13045-022-01293-5. PMID: 35659326 Free PMC Article

Follicular Lymphoma: a Focus on Current and Emerging Therapies.

Cahill KE, Smith SM
Oncology (Williston Park) 2022 Feb 8;36(2):97-106. doi: 10.46883/2022.25920946. PMID: 35180337 Free PMC Article

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

Enteropathy-Associated T cell Lymphoma.

Al Somali Z, Hamadani M, Kharfan-Dabaja M, Sureda A, El Fakih R, Aljurf M
Curr Hematol Malig Rep 2021 Apr;16(2):140-147. Epub 2021 May 19 doi: 10.1007/s11899-021-00634-4. PMID: 34009525

See all (194)

Therapy

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.

Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D, Du B, Liu M, Huang H
Nature 2022 Sep;609(7926):369-374. Epub 2022 Aug 31 doi: 10.1038/s41586-022-05140-y. PMID: 36045296 Free PMC Article

How we treat NK/T-cell lymphomas.

Tse E, Zhao WL, Xiong J, Kwong YL
J Hematol Oncol 2022 Jun 3;15(1):74. doi: 10.1186/s13045-022-01293-5. PMID: 35659326 Free PMC Article

CAR T-cell therapy for B-cell lymphoma.

Denlinger N, Bond D, Jaglowski S
Curr Probl Cancer 2022 Feb;46(1):100826. Epub 2021 Dec 25 doi: 10.1016/j.currproblcancer.2021.100826. PMID: 35012754 Free PMC Article

Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.

Abramson JS
Transfus Med Rev 2020 Jan;34(1):29-33. Epub 2019 Aug 29 doi: 10.1016/j.tmrv.2019.08.003. PMID: 31677848

See all (370)

Prognosis

Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.

Trabolsi A, Arumov A, Schatz JH
Blood Cancer J 2024 Feb 8;14(1):27. doi: 10.1038/s41408-024-00997-w. PMID: 38331870 Free PMC Article

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.

How we treat NK/T-cell lymphomas.

Tse E, Zhao WL, Xiong J, Kwong YL
J Hematol Oncol 2022 Jun 3;15(1):74. doi: 10.1186/s13045-022-01293-5. PMID: 35659326 Free PMC Article

Enteropathy-Associated T cell Lymphoma.

Al Somali Z, Hamadani M, Kharfan-Dabaja M, Sureda A, El Fakih R, Aljurf M
Curr Hematol Malig Rep 2021 Apr;16(2):140-147. Epub 2021 May 19 doi: 10.1007/s11899-021-00634-4. PMID: 34009525

Chimeric antigen receptor T cells for sustained remissions in leukemia.

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA
N Engl J Med 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222. PMID: 25317870 Free PMC Article

See all (318)

Clinical prediction guides

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.

How we treat NK/T-cell lymphomas.

Tse E, Zhao WL, Xiong J, Kwong YL
J Hematol Oncol 2022 Jun 3;15(1):74. doi: 10.1186/s13045-022-01293-5. PMID: 35659326 Free PMC Article

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.

Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ
J Clin Oncol 2021 Jun 20;39(18):1959-1970. Epub 2021 Mar 19 doi: 10.1200/JCO.20.03175. PMID: 33739857 Free PMC Article

Chimeric antigen receptor T cells for sustained remissions in leukemia.

See all (143)

Recent systematic reviews

Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.

Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A, Pasquini MC, Kröger N
Transplant Cell Ther 2024 Jun;30(6):584.e1-584.e13. Epub 2024 Jan 26 doi: 10.1016/j.jtct.2024.01.074. PMID: 38281590

Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.

Wang Z, Zhou H, Xu J, Wang J, Niu T
Front Immunol 2022;13:1070660. Epub 2023 Jan 4 doi: 10.3389/fimmu.2022.1070660. PMID: 36685572 Free PMC Article

Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.

Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M
Cochrane Database Syst Rev 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PMID: 34515338 Free PMC Article

Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell Lymphoma.

Peng YY, Xiong YY, Zhang LX, Wang J, Zhang HB, Xiao Q, Guo SL
Turk J Haematol 2021 Jun 1;38(2):126-137. Epub 2021 Feb 4 doi: 10.4274/tjh.galenos.2021.2020.0438. PMID: 33535731 Free PMC Article

Advances and Perspectives in the Treatment of T-PLL.

Braun T, von Jan J, Wahnschaffe L, Herling M
Curr Hematol Malig Rep 2020 Apr;15(2):113-124. doi: 10.1007/s11899-020-00566-5. PMID: 32034661 Free PMC Article

See all (6)

MedGen

National Center for Biotechnology Information

Send to:

Refractory Aggressive T-Cell Non-Hodgkin Lymphoma

Definition

Term Hierarchy

Professional guidelines

PubMed

Recent clinical studies

Etiology

Diagnosis

Therapy

Prognosis

Clinical prediction guides

Recent systematic reviews

Supplemental Content

Table of contents

Practice guidelines

Related information

Recent activity